Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Sickle Cell Disease — Disease-Modifying Therapy

First-line Second-line Later-line SECOND-LINE THIRD-LINE / LATER Sickle cell disease (HbSS / Sβ0) Foundation Add-on (recurrent VOC / anemia) Curative All with VOC Hydroxyurea ↑ HbF, ↓ crises ↓ VOC Crizanlizumab SUSTAIN ↗ ↑ Hb Voxelotor HOPE ↗ ↓ VOC L-glutamine adjunct Transplant Allogeneic HSCT matched donor Gene therapy exa-cel / lovo-cel selected patients